Risk factors of influenza (H1N1) 2009 hospitalization and effectiveness of pharmaceutical and nonpharmaceutical interventions in its prevention. A case-control study;Factores de riesgo de hospitalización por gripe (H1N1) 2009 y efectividad de intervenciones farmacológicas y no farmacológicas en su prevención. Estudio de casos y controles

Revista Espanola de Salud Publica

Volumn 85, Issue 1, 2011, Pages 3-15

  Domínguez, Angela ^a,f   Alonso, Jordi ^a   Astray, Jenaro ^b   Baricot, Maretva ^a   Cantón, Rafael ^a   Castilla, Jesús ^a   Castro, Ady ^c   Delgado, Miguel ^a   Godoy, Pere ^a   Gónzález Candelas, Fernando ^a   Martín, Vicente ^a   Mayoral, José María ^b   Quintana, José María ^a   Perea, Emilio ^a   Pumarola, Tomás ^d   Soldevila, Nuria ^a   Tamames, Sonia ^e  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b Servicio de Vigilancia de la Comunidad   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Red Espanola de Investigacion en Patologia Infecciosa REIPI   (Spain)

^e Direccion General de Salud Publica   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Case control studies; Effectiveness; Influenza vaccines; Personal hygiene; Streptococcus pneumoniae

Indexed keywords

ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; MULTICENTER STUDY; RISK FACTOR; SPAIN; STATISTICS;

CASE-CONTROL STUDIES; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; RISK FACTORS; SPAIN;

EID: 79960284400     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Wright PF, Neumann G, KawaokaY. Orthomyxoviruses. En: Knipe DM, Howley PM, editores. Fields Virology. 5th ed. Philadelphia: Wolters Kluwer; 2007.p.1691-740.
2. Treanor JJ. Influenza viruses, including avian influenza and swine influenza. En: Mandell GL, Bennett JE, Dolin R, editores. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2010.p. 2265-88.
3. Miller MA, Vibourd C, Balinska M, Simonsen L. The signature features of influenza pandemics-implication for policy. N Engl J Med. 2009; 360:2595-8.
4. CDC. Swine influenza A(H1N1) infection in two children-Southern California, March-April 2009. MMWR. 2009; 58: 400-2.
5. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007; 12:603-16. (Pubitemid 47235503)
6. Cher SM, Wagstaff AJ. Zanamivir. An update of its use in influenza. Drugs. 2002; 62: 71-106. (Pubitemid 34169427)
7. Moscano SA. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353: 1363-73.
8. Lee VJ, Yap J, Cook AR, Chen MI, Joshua KT, Tan BH et al. Oseltamivir ring prophylaxis for containment of 2009 (H1N1) influenza outbreaks. N Engl J Med. 2010; 362: 2166-74.
9. Kar-Purkayastha I, Ingram C, Maguire H, Roche A. The importance of school and social activities in the transmission of influenza A(H1N1)v: England, April -June 2009. Euro Surveill. 2009; 14: 174-7.
10. Jefferson T, JonesM, Doshi P, del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009; 339: b5106.
11. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005; 11:1-12.
12. Falagas M, Koletsi P, Vouloumanou E, Rafailidis P, Kapaskelis AM, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemoth. 2010; 65: 1330-1346.
13. Jain S, Kamimoto L, Bramley A, Schmitz AM, Benoit SR, Louie J et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. New Engl J Med. 2009; 361: 1935-44.
14. Herrera GA, Iwanwe MK, Cortese M, Gershman K, Shipe A, Averhoff F et al. Influenza vaccine effectiveness among 50-64 years-old persons during a season of poor antigenic match between vaccine and circulating influenza strains. Colorado, United States, 2003-2004. Vaccine. 2007; 25: 154-60. (Pubitemid 44855254)
15. Nichol KL, Lind A, Margolis KL, Murdoch M, McFaden R, Hauge M et al. The effectiveness of vaccination against influenza in healthy working adults. N Eng J Med. 1995; 333: 889-93.
16. Jefferson TO, Rivetti D, Di Pietrantonj, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007; CD001269.
17. a ed. Philadelphia: Saunders; 2008.p. 259-90.
18. Fine AD, Bridges CB, Dde Guzman AM, Glover L, Zeller B, Wong SJ et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York. Clin Infect Dis. 2001; 32: 1784-91. (Pubitemid 32532009)
19. Govaert TM, Thijs CT, Masurel N, Sprenger JW, Dinant GJ, Knottnerus SA . The efficay of influenza vaccination in the elderly individuals . A randomized double-blind placebo-controlled trial. JAMA. 1994; 272-1661-5. (Pubitemid 24359136)
20. Jefferson T, Rivetti D, Rivetti A et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematixc review. Lancet. 2005; 3666: 1165-74. (Pubitemid 41393594)
21. Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A(H3N2) epidemic. JAMA. 1985; 253: 1136-9. (Pubitemid 15103822)
22. Nichol KL, Nordin JD, Nelson DB, Mullooly JR, Hak E. Effectiveness of influenza vaccine in the community dweling elderly. N Engl J Med. 2007; 357: 1373-81. (Pubitemid 47535592)
23. Jackson LA, Nelson JC, Benson P, Neuzil M, Reid RT, Psaty BM et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in senior. Int J Epidemiol. 2006; 35: 345-52.
24. Simonsen L, Viboud C, Taylor RF. Effectivenes of influenza vaccination. N Engl J Med. 2007; 357: 2729- 30.
25. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE et al. Vaccines for preventing influenza for elderly. Cochrane Databse Syst Rev. 2010; CD004876.
26. Jefferson T, Rivetti T, Harnden A, Di Pietyrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008; CD004879.
27. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for pandemic and seasonal influenza vaccination of school-children in the United States.Am J Epidemiol. 2009; 170: 679-86.
28. Domínguez A, Salleras L, Fedson D, Izquierdo C, Ruiz L, Ciruela P et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia: a case control study. Clin Infect Dis 2005; 40:1250-7. (Pubitemid 40570233)
29. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN study. Clin Infect Dis. 2006; 43: 860-8. (Pubitemid 44435513)
30. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams A et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003; 348:1747-55. (Pubitemid 36514705)
31. Nichol KL. The additive benefits of influenza and pneumococcal vaccination during an influenza season among elderly persons with chronic lung diseases. Vaccine. 1999; 17 (suppl. 1):S91-3. (Pubitemid 29366942)
32. Wagner C, Popp W, Posch M, Vlasich C, Rosenberg-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a casecontrolled study. Gerontology. 2003;49:246-50. (Pubitemid 36693859)
33. Vila-Córcoles A, Salsench E, Rodriguez-Blanco T, de Diego C, Valdivieso A, Hospital J et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009; 27:1504-10.
34. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas J-M et al. Effectiveness of the pneumococcal polysaccharide vaccine in Preventing Pneumonia in the elderly. Eur Respir J. 2010; 36: 608-614.
35. Ansaldi F, Turello V, Lai P, Bartone G, de Luca S, Rosselli R et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a largescale retrospective cohort study. J Int Med Res. 2005; 33:490-500. (Pubitemid 41388386)
36. Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, Campbel D. Prevention of community- acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine. 2007; 25:4631-40. (Pubitemid 46734530)
37. Madhi SA, Klugman KP and the Vaccine Trialist Group. A role for the Streptococcus pneumoniae in virus-associated pneumoniae. Nat Med. 2004; 10: 811- 3.
38. Rubin Jl, McGarry LJ, Lugman KP, Strutton DR, Gilmore KE, Weinstein MC. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine ( PCV7) in the context of the annual epidemic and a severe influenza pandemic. BMC Infect Dis. 2010; 21 ( 10): 14.
39. Louie J, Jean C, Chen TH, Park S, Ueki R, Harper T et al. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenzaA(H1N1)- United States, May- August 2009. MMWR. 2009; 58:1- 4.
40. Shanon S, Louie J, Siniscalchi A, Rico E, Ritcher D, Hernández R et al. Surveillance of pediatric deaths associated with 2009 pandemic A (H1N1) virus infection- United States, April- August 2009. MMWR. 2009; 58:941-7.
41. ECDC. Personal (non-pharmaceutical) protective measures for reducing transmission of human influenza- Interim ECDC Recommendations, October 2006.
42. Ryan MA, Christian RS, Wolrabe J. Handwashing and respiratory illness among young adults and military training.Am J Prev Med. 2001; 21: 79-82.
43. Wu J, Xu F, ZhouW, Feikin DR, Lin CY, He X et al. Risk factors for SARS among persons without known contacts with SARS patients, Beijing, China. Emerg Infect Dis. 2004; 10: 210-6. (Pubitemid 38176957)
44. Lau JTF, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. Emerg Infect Dis. 2004; 10: 587-92. (Pubitemid 38420288)
45. HeymanA, Chodik G, Reichman B, Kokia E, Laufer J. Influence of school closure on the incidence of viral respiratory diseases among children and on health care utilization. Pediatr Infect Dis J. 2004; 23: 675-7. (Pubitemid 38924896)
46. Cauchemez S, Valleron AJ, Boëlle P-Y, Flahault A, Fergusson NM. Estimating the impact of school closure on influenza transmission from sentinel data. Nature. 2008; 452:750-4. (Pubitemid 351521077)
47. Wu JT, Cowling BJ, Lau E HY, Ip KM, Ho LM, Tsang T et al. School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerg Infect Dis. 2010; 16: 538-41.
48. Kahn LH. Pandemic influenza school closure policies. Emerg Infect Dis. 2007; 13: 344-5. (Pubitemid 46193191)
49. Effer PV, Carcione D, Giele C, Dowse GK, Goggin L, Mak DB. Household response to pandemic (H1N1) 2009 -related school closures, Perth, Western Australia. Emerg Infect Dis. 2010; 16: 205-11.
50. Hatchet TJ, Mecher CE, Lipsitch M. Public health interventions and epidemicintensity during the 1919 influenza pandemic.PNAS. 2007;104: 7582-7. (Pubitemid 47185949)
51. Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, SternAM, Cetron MS. Nonpharmaceutical inerventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA.2007; 298: 643- 54.
52. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS . Strategies for mitigating an influenza pandemic. Nature. 2006; 442: 448-51.
53. Schlesselman JJ. Case-control studies. Design, conduct, analysis. New York: Oxford University Press; 1982.p.144-70.
54. Menikoff J. The paradoxical problem with multiple- IRB review. N Engl J Med. 2010; 363:1591-93.
55. Cowling BJ, Chan K H, Fang VJ, Lau LH, So HC, Fung ROP, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med. 2010; 362: 2175-84.
56. Cilla G, Pérez-Trallero E. Pandemia de influenza A(H1N1) 2009, 6 meses de experiencia. Med Clin (Barc). 2010; 135:21-2.